04.10.19

STAAR Surgical Celebrates 1 Million Lens Milestone for Implantable Collamer Lens

Source: STAAR Surgical

STAAR Surgical announced that more than 1 million Visian implantable collamer lenses (ICLs) have been implanted globally. Currently approved versions of the ICL available in more than 75 countries around the world address the explosive growth of myopia, the need for distance vision correction, that is predicted to affect 50% of the world’s population by 2050. 

“We celebrate the Visian ICL 1 million lens milestone with our ophthalmology partners, clinicians, and patients who are elevating the ICL to the premium and primary solution for refractive based vision correction,” said Caren Mason, President and CEO of STAAR Surgical. “More ICLs have been implanted since 2015 than the prior 15 years of the ICL combined. Today’s milestone represents only the beginning of our journey in raising ICL awareness and adoption to delight surgeons and their patients. The ICL, a remarkable biocompatible lens that works in harmony with a person’s natural eye, is designed to improve vision following a quick 20- to 30-minute procedure that many patients have described as ‘life changing.’ Through our ICL family of lenses STAAR aims to significantly increase our share of the existing 4 million annual refractive procedures globally, facilitate the market’s return to peak procedure volumes, and further grow the overall market with new and innovative lenses that address customer demands such as a refractive solution for presbyopia that may eliminate the need for reading glasses. Our work toward future milestones will be bolstered by strong clinical evidence, surgeon training, and ongoing operating and financial discipline.”

The Visian ICL family of lenses are phakic intraocular lenses designed to correct for a wide range of vision correction needs including myopia, hyperopia, and astigmatism. The lenses are quiet in the eye. STAAR introduced the first ICL for myopia in 1997. US sales commenced in 2006 followed by the introduction of the ICL with CentraFLOW technology outside the United States in 2011, which is now marketed as the EVO Visian ICL. EVO lenses have a port in the center of the ICL optic intended to eliminate the need for a peripheral iridotomy procedure days before the ICL implant. In 2016, STAAR launched Evolution in Visual Freedom websites in major markets, rolled out new marketing material for surgeons and patients, introduced the EVO+ for larger pupil sizes, and began entering into strategic cooperation agreements with leading ophthalmology clinics and surgeons that position the ICL as a premium and primary refractive procedure for vision correction.

Related Content